Efficacy Results from a 12-month Double-blind Randomized Trial of Arimoclomol for Treatment of Niemann Pick Disease Type C – Presenting an Improved 4-Domain NPC Clinical Severity Scale
Thursday, September 5, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses the efficacy results from a 12-month double-blind randomized trial of Arimoclomol for treating Niemann Pick Disease Type C. The study introduces an improved 4-domain NPC clinical severity scale, highlighting the treatment's potential benefits. The results will be presented at the Society for the Study of Inborn Errors of Metabolism's 2024 Annual Symposium.
Price reaction · baseline $7.19 (2024-09-04 close) · hit pre-market · 4 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows promising efficacy in treating Niemann Pick Disease Type C.
The trial utilized an improved 4-domain NPC clinical severity scale.
Results presented at a reputable symposium indicate strong interest in the findings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Efficacy Results from a 12-month Double-blind Randomized Trial of Arimoclomol for Treatment of Niemann Pick Disease Type C – Presenting an Improved 4-Domain NPC Clinical Severity Scale
Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium - 09/06/2024
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is being investigated for its efficacy in treating Niemann Pick Disease Type C.
What was the duration of the trial?
The trial lasted for 12 months.
Where will the trial results be presented?
The results will be presented at the SSIEM 2024 Annual Symposium.
What is the new clinical severity scale introduced?
An improved 4-domain NPC clinical severity scale was introduced in the trial.